Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

This study is ongoing, but not recruiting participants.

First Received: April 5, 2002 Last Updated: October 23, 2007 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00033072

Purpose

The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.

Condition	Intervention	Phase
Amphetamine-Related Disorders	Drug: Selegiline	Phase I

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Placebo Control
Official Title:	Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline

Resource links provided by NLM:

MedlinePlus related topics: Methamphetamine

Drug Information available for: Methamphetamine hydrochloride Selegiline Selegiline hydrochloride Amphetamine Methamphetamine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

safety of selegiline
pharmacokinetic assessment

Estimated Enrollment:	16
Study Start Date:	September 2001
Estimated Study Completion Date:	October 2002

Detailed Description:

To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals
Be able to verbalize understanding of consent form; provide written informed consent

Exclusion Criteria:

Please contact site for more information

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00033072

Locations

United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Thomas Newton, M.D.

University of California, Los Angeles

More Information

No publications provided

Study ID Numbers:	NIDA-CTO-0004-1
Study First Received:	April 5, 2002
Last Updated:	October 23, 2007
ClinicalTrials.gov Identifier:	NCT00033072 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Anti-Dyskinesia Agents
Adrenergic Uptake Inhibitors
Physiological Effects of Drugs
Antiparkinson Agents
Disorders of Environmental Origin
Neuroprotective Agents
Mental Disorders
Therapeutic Uses
Substance-Related Disorders

Monoamine Oxidase Inhibitors
Sympathomimetics
Central Nervous System Stimulants
Enzyme Inhibitors
Protective Agents
Pharmacologic Actions
Selegiline
Methamphetamine
Autonomic Agents
Amphetamine-Related Disorders
Dopamine Agents
Amphetamine
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 27, 2009